Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge
Portfolio Pulse from
Altimmune's drug Pemvidutide is undergoing a phase 2b study for MASH treatment, with results expected in Q2 2025. The MASH market is projected to reach $7.64 billion by 2031. A successful FDA meeting for Pemvidutide in obesity treatment will lead to four phase 3 trials next year.
November 13, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune's Pemvidutide is in phase 2b trials for MASH, with results due in 2025. The MASH market is expected to grow significantly. A successful FDA meeting for obesity treatment will lead to phase 3 trials, potentially boosting Altimmune's market position.
The phase 2b trial of Pemvidutide for MASH and the expected growth of the MASH market suggest potential future revenue streams for Altimmune. The successful FDA meeting for obesity treatment indicates regulatory progress, which is crucial for advancing to phase 3 trials. These developments are likely to positively impact Altimmune's stock in the short term.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90